The Food and Drug Administration (FDA) is facing mounting criticism over the timeline and data used in its safety review of the abortion drug mifepristone.
Posted Oct 09, 2026
Posted Oct 02, 2026
Posted Sep 28, 2026
Posted Sep 25, 2026
Posted Sep 18, 2026
Posted Sep 15, 2026
Posted Sep 09, 2026
Posted Sep 03, 2026
Posted Sep 01, 2026
October 16, 2026 Hear More